SB/Block Deal Brings Small Rx Line, OTC Options To Glaxo Merger
Executive Summary
SmithKline Beecham's acquisition of Block Drugs solidifies SB's number three position in the U.S. toothpaste market - and may increase the options for handling the consumer products business after the Glaxo/SmithKline merger.
You may also be interested in...
GlaxoSmithKline Merger Delayed While FTC Looks For "Smoking" Gun
The Glaxo and SmithKline smoking cessation product lines are the latest focus of scrutiny during the antitrust clearance process for the two companies' proposed merger.
Glaxo SmithKline Sees Consumer Internet Experience Helping Rx Strategy
Glaxo Wellcome is using the Internet to conduct virtual sales calls with physicians who refuse to see sales reps.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011